Bladder Drug Manufacturers Face Lawsuits Over Retinal Damage Linked to Elmiron

On Wednesday, August 12th, women in two separate complaints filed suit against units of Johnson & Johnson, Bayer and Teva Pharmaceuticals USA Inc. after they developed eye damage after taking bladder medication Elmiron. Here, the pharmaceutical liability attorneys at Peter Angelos P.C. discuss the latest updates in Elmiron litigation and what it means for patients currently taking Elmiron.

Units of Drug Manufacturers Sued Over Impaired Vision Caused by Elmiron

According to Law360, two women allege that their impaired vision is linked to Elmiron (pentosan polysulfate sodium), a popular bladder drug manufactured by drug corporations J&J, Bayer and Teva Pharmaceuticals. Their separate complaints, filed in a New Jersey Federal Court on Wednesday, August 12th, claim that their visual ailments were caused by taking Elmiron, which was prescribed to them as a treatment for their interstitial cystitis. The two plaintiffs, Clara Johns and Shirley Ruth Levy, took prescription Elmiron for years to treat their bladder conditions.

After taking Elmiron as prescribed by their doctors, the two plaintiffs now suffer from retinal damage which includes blurred vision, toxic maculopathy and other eye damage. They claim that the drug manufacturers held knowledge that Elmiron usage could cause retinal damage, but did not warn doctors or patients of the potential side effects. 

According to the Complaints, Decades of Research Point to Elmiron’s Harmful Effects on Vision

In their separate complaints, Johns and Levy claim that studies from the 1980s and 1990s show that pentosan polysulfate sodium may be linked to vision ailments. Despite this research, major drug manufacturers failed to properly inform the public and the medical community of the risks associated with bladder medication Elmiron. The plaintiffs also claim that manufacturers like J&J, Beyer and Teva Pharmaceuticals knew that the human body did not easily absorb Elmiron, and that potentially up to 94% of the drug could be excreted or absorbed into other epithelial cells, such as cells in the retina. Additionally, the plaintiffs claim that Elmiron merely coats the epithelial cells in the bladder, providing pain relief but failing to actually treat interstitial cystitis. 

The plaintiffs’ claims point to the possibility that pharmaceutical manufacturers failed to properly test Elmiron to the full extent necessary to ensure patient safety. The plaintiffs argue that these manufacturers purposely covered up the risks of taking Elmiron, which led to a significant delay in the plaintiffs discovering the link between Elmiron and eye damage.

The Pharmaceutical Liability Attorneys at Peter Angelos P.C. are Actively Taking Elmiron Cases

When a major pharmaceutical company actively hides the potential adverse reactions of a popular drug, they are standing by as thousands of patients unknowingly subject themselves to these harmful side effects. That is why the team of pharmaceutical liability attorneys at Peter Angelos, P.C. are passionate about representing victims who suffer at the hands of corrupt corporations who fail to carry out the appropriate measures of thorough testing and transparency. Peter Angelos, P.C. is actively taking Elmiron cases—if you or someone you know now suffers from vision impairment after taking Elmiron to treat their bladder condition, contact our Baltimore office immediately to request a free consultation. 

 

DISCLAIMER: Information in this article was sourced from Law360.